A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer
- Resource Type
- Article
- Source
- In
Clinical Breast Cancer February 2019 19(1):1-9 - Subject
- Language
- ISSN
- 1526-8209